Every letter we have printed

You describe the maintenance strategy of stepping down one dose and holding for eight to twelve weeks as something clinicians report doing, and then say it is not a recommendation. That distinction will be lost on most readers, and printing the protocol makes you a source for it whether you intend to be or not.

Three months after stopping, my HbA1c had barely moved and I concluded I had got away with it. Six months after stopping, it was back where it started. Your point about the lag is the single most useful sentence I have read on this subject.

You say no dose-equivalence data exists between agents in this class. During the shortage my pharmacy substituted one for another on the basis of a conversion table they had printed from somewhere. Where would such a table have come from?

As a prescriber I would push back on your framing of the maintenance gap. We are not practising without evidence; we are practising on pharmacological inference, which is what clinicians do in every field where the trial has not been run. Calling it unevidenced makes reasonable practice sound reckless.

I lost access for eleven weeks during the shortage, restarted at the dose I had been on because nobody told me otherwise, and spent a fortnight unable to keep food down. I had been on that dose for seven months without difficulty. Reading your resumption section was the first time anybody explained it.

Your piece describes tapering as pharmacologically pointless and then spends three paragraphs making a case for it. Pick one.

Acting on your section about system suitability, I asked a laboratory whether the criteria had been met on my run. They sent the suitability summary the same afternoon, unprompted and without charge, and it showed a tailing factor of 1.3 and replicate agreement well inside a per cent. Nothing was being withheld. Nobody had ever asked.

I want to push back on the ginger paragraph. You describe the evidence as transferred from pregnancy and chemotherapy, which is accurate, and then include it in the table anyway. Either it belongs or it does not.

Your figures show diarrhoea at thirty-two per cent and constipation at twenty-three per cent in the same trial arm. I assumed one of these was an error until your mechanism section. It would be worth putting that explanation before the table rather than after it.

The gallbladder section says some of the excess is attributable to weight loss rather than the drug. If the drug causes the weight loss, is that not a distinction without a difference for the person who ends up in theatre?

As an anaesthetist I read the perioperative section with interest and one objection. You frame disclosure as the patient obligation. In my experience the failure is more often ours: the pre-assessment questionnaire in my own institution did not include these drugs until eighteen months after the first guidance appeared.

Nothing in your file addresses the social dimension, which for me was worse than the nausea. Six months of declining invitations to meals, and explaining to family why I was not eating. The tables do not have a row for that.

Thank you for saying plainly that the maximum dose is not the goal. I stopped at 10 mg fourteen months ago because it was working and I was tired of arguing about it. Every article I read before yours implied I had given up early.

Your suggestion that laboratories publish the fact of a submission while keeping the result confidential is the first proposal I have read in this area that a laboratory could actually implement without breaching a client obligation. I have raised it internally.

You disclose that two of these services advertise with you and then spend four thousand words on structural criticism of the sector they operate in. I cannot decide whether that is admirable independence or an elaborate way of appearing independent. Probably the former. I wanted to say that I noticed the question.

I submitted a vial to one of these services last year, got a result three points below what the vendor advertised, and did not know what to do with it. Your article explains why: I had one measurement on one vial, no method comparison, and no way to know if my vial was representative. I still do not know what to do with it, but I understand the shape of not knowing.

I run analytical services and I object to the framing of your blind comparison. You bought our cheapest tier, published the number it produced alongside a competitor’s most thorough package, and called the result a spread. It is not a spread. It is three different products, priced accordingly, and your own table says so two columns to the right of the headline figure.

VendorInvestigate does not measure anything and you have grouped it with three laboratories under the heading independent testing. That is exactly the conflation your article says the market makes.

Your article says a matching mass does not confirm a sequence, which is correct, and then rather implies that vendors are trading on the ambiguity. I run analytical services and I would put it differently: we report what we measured, in the words our clients ask for. If the Journal wants the word confirmed retired, write to the buyers, not to us.

You describe the low-T3 pattern during energy restriction as benign adaptation. There is a body of opinion holding that it represents a genuine hypometabolic state requiring treatment. I do not hold that view but your readers will encounter it.

My HbA1c was 6.1 before starting and 6.0 after four months. My clinic recorded this as no improvement in glycaemic control. My continuous monitor says my average glucose fell by a fifth over the same period. Which is measuring what?

As a buyer I found the section on who chose the vial genuinely clarifying and slightly deflating. I have been treating vendor-published reports as equivalent to my own submissions for two years, and on your account they are not equivalent by an amount that cannot be measured.

Your selection-effect model assumes a supplier publishes results above a fixed threshold. Real behaviour is surely more complicated: a supplier might publish a poor result on a batch it has withdrawn, or publish everything for a period to establish credibility and then stop. The arithmetic is fine and the behavioural assumption is a cartoon.

VendorInvestigate does not measure anything and you have grouped it with three laboratories under the heading independent testing. That is exactly the conflation your article says the market makes.

On the archive point: a public record of submissions by vendor would be gamed within a month. Vendors would submit under the names of resellers, or through intermediaries, and the archive would show a distribution as selected as the current one but with a veneer of completeness.

I submitted a vial to one of these services last year, got a result three points below what the vendor advertised, and did not know what to do with it. Your article explains why: I had one measurement on one vial, no method comparison, and no way to know if my vial was representative. I still do not know what to do with it, but I understand the shape of not knowing.

A quibble on your dead-space figure. You give two to seven microlitres for insulin-type needles, which is right for fixed-needle syringes, but the detachable pen needle plus syringe hub combinations sold in this market are considerably worse and you should say so.

You spend a page on the four-line calculation and then publish a reconstitution table anyway. Are you not providing exactly the pre-computed number you warned against?

On the archive point: a public record of submissions by vendor would be gamed within a month. Vendors would submit under the names of resellers, or through intermediaries, and the archive would show a distribution as selected as the current one but with a veneer of completeness.

VendorInvestigate does not measure anything and you have grouped it with three laboratories under the heading independent testing. That is exactly the conflation your article says the market makes.

Your selection-effect model assumes a supplier publishes results above a fixed threshold. Real behaviour is surely more complicated: a supplier might publish a poor result on a batch it has withdrawn, or publish everything for a period to establish credibility and then stop. The arithmetic is fine and the behavioural assumption is a cartoon.

Your piece assumes readers have a clinician ordering panels for them. A great many of us are buying our own, from services that supply an interval, a flag and nothing else. The apparatus you describe is not available to us at all.

Correction to your HbA1c section. You write that chronic kidney disease lowers HbA1c through shortened erythrocyte survival. It can also raise measured values on some assay platforms through carbamylated haemoglobin interference. The net direction depends on the method.

A small thing but it matters in practice: your table gives amylase and lipase rising as a finding of unclear significance. In my laboratory we no longer report amylase at all for suspected pancreatitis, because lipase is more sensitive and more specific and having both invites the wrong one to be acted on.

My ferritin fell from 118 to 34 across a year on treatment and I was told this was expected because inflammation had fallen. Six months later I was clearly iron deficient. I appreciate the section on this being ambiguous, but the ambiguity was resolved in one direction and nobody looked.

Your worked example varies gradient and threshold together and reports a 1.8-point spread. Which of the two contributed more? The article does not say, and the answer matters for what you are asking suppliers to disclose first.

Something your article omits, and it changes where the responsibility sits. Method selection is frequently specified by the customer, not by us. A purchase order arrives asking for a peptide purity run at a stated price and turnaround, and the method that fits those two constraints is the method that runs. We are perfectly willing to develop a longer separation for anybody who wants one, and in eleven years almost nobody has asked.

You write that only one laboratory attached its chromatogram to the private buyer report. That was probably us. We started doing it five years ago because the PDF seemed incomplete without it. It costs us nothing to add — the instrument generates it automatically — and it solves exactly the dispute-resolution problem you describe. More laboratories should do it, and the reason they do not is not technical.

On the section about diode-array detection and peak purity, I would add that true peak purity assessment requires library matching or at least spectral comparison across the peak width. A homogeneous spectrum tells you the peak is probably pure. A spectrum that shifts across the peak tells you it is not, and that information closes a gap the article identifies correctly.

The table showing what each method can detect is valuable but incomplete. You show no row for C-terminal truncation or N-terminal truncation as distinct phenomena. These are not rare, and they often elute differently depending on which end is missing. A generic gradient might resolve them; an improperly designed orthogonal method might not. The capability matrix should separate these cases.